Biotech News
Syndax Reports Preliminary 2025 Financial Highlights and Provides Business Updates at the 44th Annual J.P. Morgan Healthcare Conference
ir.syndax.com2026-05-06 14:52 EST
– Approximately $44 million and $125 million in preliminary (unaudited) Revuforj ® (revumenib) 4Q25 and full year 2025 net revenue, respectively – – Continued acceleration in demand following approval in R/R NPM1m AML, with an approximate 38% increase in Revuforj net revenue in 4Q25 vs.